Extended Group Written Exposure Therapy for Comorbid PTSD and BPD (Traits)
4 mai 2026 mis à jour par: Jennifer Ip, St. Joseph's Healthcare Hamilton
The goal of this open label trial is to evaluate the effectiveness of virtual group extended Written Exposure Therapy (GE-WET) in reducing Post-Traumatic Stress Disorder (PTSD) symptoms in patients with comorbid PTSD and Borderline Personality Disorder (BPD) or BPD traits. GE-WET involves attending weekly 2-hour group WET sessions for the duration of 10 weeks, in which they write about their trauma experience using specific instructions.
This study will be conducted at St. Joseph's Healthcare Hamilton's Community Psychiatry Clinic with clients wait listed for PTSD treatment (ages 18- 65, any gender, co-morbid PTSD and BPD/BPD traits).
The main questions this study aims to answer are:
Does GE-WET reduce PTSD symptoms (based on PCL-5 measures) in this population (outpatient clients ages 18-65 of any gender, with a diagnosis of PTSD and BPD or BPD traits)?
Does GE-WET result in reduced drop-out rates for this population, compared to that of other evidence-based treatment for PTSD?
What are participants subjective experience of GE-WET?
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
63
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Ontario
-
Hamilton, Ontario, Canada
- St. Joseph's Healthcare Hamilton
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Reading and writing proficiency in English
- Access to an electronic device to attend virtual group meetings
- Age 18-65
- Previous diagnosis of Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD)/BPD traits
- Completion of a DBT skills group via St. Joe's Community Psychiatry Clinic
Exclusion Criteria:
- Diagnosis of an active severe substance use disorder or psychotic disorder
- Untreated active psychotic symptoms, mania, or hypomania
- Has attempted suicide in the 2 months prior to treatment beginning
- Has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment
- Has completed Cognitive Processing Therapy or another active PTSD treatment (i.e., prolonged exposure) in the past year
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group Extended Written Exposure Therapy
Participants will be invited to participate in group extended Written Exposure Therapy (described in the Interventions section).
|
Group Extended Written Exposure Therapy (GE-WET) is a time-limited cognitive behavioural therapy for Posttraumatic Stress Disorder (PTSD) aimed at allowing patients to process their traumatic experiences in a safe environment.
GE-WET will consist of 10 weekly group sessions.
Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience.
The written exposure will be followed by a guided discussion about the experience of writing the exposure.
There is no homework assigned between sessions.
However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
PTSD Checklist for DSM-5 (PCL-5)
Délai: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Posttraumatic Cognitions Inventory
Délai: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
A 36-item self-report questionnaire that assesses negative thoughts across three subscales: negative cognitions about the self (e.g., "I am a weak person"), negative cognitions about the world (e.g., "I have to be on guard all the time"), and self-blame (e.g., "the event happened because of the way I acted").
The PTCI has demonstrated good internal consistency, test-retest reliability, and convergent validity with other measures of posttraumatic cognitions.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Borderline Symptom List- Short Version (BSL-23)
Délai: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The BSL-23 is a 23-item self-report measure that assesses for DSM borderline personality disorder symptomatology as well as associated problems such as self-criticism, loneliness, helplessness, and problems with trust.
The BSL-23 has demonstrated high internal consistency and test-retest reliability, and strong convergent validity with correlations with depression and general psychopathology severity.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Borderline Symptom List Behaviour Supplement
Délai: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The BSL-23 Behaviour Supplement is an 11-item supplemental measure used to assess frequency of problematic behaviours (e.g., non-suicidal self-injury, suicide attempts, suicidal communication, angry outbursts, misuse of substances, etc.) associated with borderline personality disorder.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Toronto Alexithymia Scale-20 (TAS-20)
Délai: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The TAS-20 is a 20-item self-report measure assessing for alexithymia (i.e., issues in identifying and processing emotions) across three factors: difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking.
The TAS-20 has demonstrated adequate levels of convergent validity, good internal consistency, and good test-retest reliability.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Experience of Shame Scale (ESS)
Délai: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The ESS is a 25-item self-report measure assessing characterological shame (e.g., shame of personal habits or personal ability), behavioural shame (e.g., shame in doing or saying something wrong), and bodily shame (e.g., shame regarding one's body).
The ESS has demonstrated good internal consistency and test-retest reliability.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Difficulties in Emotion Regulation Scale (DERS)
Délai: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
The DERS is a widely used 36-item self-report measure assessing six dimensions of emotion regulation difficulties.
The DERS demonstrates good internal consistency, convergent validity, and predictive validity of behaviours reflective of emotion regulation difficulties.
|
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
|
|
Group Cohesion Scale - Revised (GCS-R)
Délai: Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
|
The GCS-R is a self-report measure that measure's group member's perception of their group and the strength of the bonds formed.
The GCS-R showed high reliability for use in research and is sensitive to detecting changes in cohesiveness as a function of group development.
|
Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Bagby RM, Taylor GJ, Parker JD. The Twenty-item Toronto Alexithymia Scale--II. Convergent, discriminant, and concurrent validity. J Psychosom Res. 1994 Jan;38(1):33-40. doi: 10.1016/0022-3999(94)90006-x.
- Gratz, K. L., & Roemer, L. (2004). Multidimensional assessment of emotion regulation and dysregulation: Development, factor structure, and initial validation of the difficulties in emotion regulation scale. Journal of Psychopathology and Behavioral Assessment, 26, 41-54.
- Foa, E.B., Ehlers, A., Clark, D.M., Tolin, D.F., & Orsillo, S.M. (1999). The Posttraumatic Cognitions Inventory (PTCI): Development and validation. Psychological Assessment, 11(3), 303-314.
- Treadwell, T., Lavertue, N., Kumar, V. K., & Veeraraghavan, V. (2001). The Group Cohesion Scale-Revised: Reliability and validity. International Journal of Action Methods: Psychodrama, Skill Training, and Role Playing, 54(1), 3-12.
- Andrews B, Qian M, Valentine JD. Predicting depressive symptoms with a new measure of shame: The Experience of Shame Scale. Br J Clin Psychol. 2002 Mar;41(Pt 1):29-42. doi: 10.1348/014466502163778.
- Bohus M, Kleindienst N, Limberger MF, Stieglitz RD, Domsalla M, Chapman AL, Steil R, Philipsen A, Wolf M. The short version of the Borderline Symptom List (BSL-23): development and initial data on psychometric properties. Psychopathology. 2009;42(1):32-9. doi: 10.1159/000173701. Epub 2008 Nov 20.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 juin 2026
Achèvement primaire (Estimé)
1 juin 2028
Achèvement de l'étude (Estimé)
1 décembre 2028
Dates d'inscription aux études
Première soumission
20 avril 2026
Première soumission répondant aux critères de contrôle qualité
4 mai 2026
Première publication (Réel)
8 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
8 mai 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
4 mai 2026
Dernière vérification
1 mai 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 18906
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .